to mutations in

KRAS

and

TP53

. McDonald et al. found a 31% of

TP53

mutations and a 39% of

KRAS

mutations in 52 lung cancer cases

have metastatic colorectal cancer have tumors with specific molecular profiles (eg, KRAS/NRAS/BRAF wild-type tumors or those with BRAF V600E

KRAS

G12C

inhibitor adagrasib shows promising efficacy in pretreated patients with advanced non-small cell lung cancer harboring a

KRAS

: anaplastic lymphoma kinase (ALK)-fusion, epidermal growth factor receptor (EGFR), or Kirsten rat sarcoma viral oncogene homologue (KRAS)

Targetable alterations including

BRAF

V600E,

EGFR

exon 20 insertions,

KRAS

G12C mutations,

MET

exon 14 alterations,

NTRK

and

RET

version of a gene known as KRAS is present in as many as 90 percent of pancreatic cancer cases.

“The mutant form of the KRAS gene is one of

Myers Squibb on lung cancer disparities and Mirati Therapeutics on KRAS cancers.

The new additions augment Stand Up To Cancer’s pharma

the Phase 1b study of Mirati’s cancer therapy adagrasib. The patients in the study had Non-small Cell Lung Cancer that had spread to the

from the

KRAS Kickers

patient advocacy subgroup: Can we kick cancer's KRAS harder? Will we see improved efficacy with novel KRAS

G12C